Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Femke de Velde"'
Autor:
Femke de Velde, Brenda C. M. de Winter, Michael N. Neely, Jan Strojil, Walter M. Yamada, Stephan Harbarth, Angela Huttner, Teun van Gelder, Birgit C. P. Koch, Anouk E. Muller, on behalf of the COMBACTE-NET Consortium
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2170 (2021)
Population pharmacokinetic modeling and simulation (M&S) are used to improve antibiotic dosing. Little is known about the differences in parametric and nonparametric M&S. Our objectives were to compare (1) the external validation of parametric and no
Externí odkaz:
https://doaj.org/article/fd2d4162d61a43c1a8ffc404ef98d7db
Autor:
Birgit C. P. Koch, Elodie von Dach, Walter M. Yamada, Brenda C. M. de Winter, Femke de Velde, Teun van Gelder, Stéphan Juergen Harbarth, Angela Huttner, Michael Neely, Johan W. Mouton
Publikováno v:
Clinical Pharmacokinetics, 59(7), 885-898. Adis
Clinical Pharmacokinetics
Clinical Pharmacokinetics
Background Population pharmacokinetic (popPK) models for antibiotics are used to improve dosing strategies and individualize dosing by therapeutic drug monitoring. Little is known about the differences in results of parametric versus nonparametric po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::defcf33744e3631b6b6f08c98473a14d
https://pure.eur.nl/en/publications/8dd7d2ec-90b8-4951-9b61-8e26195b77de
https://pure.eur.nl/en/publications/8dd7d2ec-90b8-4951-9b61-8e26195b77de
Publikováno v:
Pharmacological Research, 134, 280-288. Academic Press
Because of increasing antimicrobial resistance and the shortage of new antibiotics, there is a growing need to optimize the use of old and new antibiotics. Modelling of the pharmacokinetic/pharmacodynamic (PK/PD) characteristics of antibiotics can su
Publikováno v:
Journal of Antimicrobial Chemotherapy, 73(2), 469-476. Oxford University Press
Objectives To calculate the clavulanic acid exposure of oral amoxicillin/clavulanic acid dosing regimens, to investigate variability using a population pharmacokinetic model and to explore target attainment using Monte Carlo simulations. Methods Two
Publikováno v:
Journal of Antimicrobial Chemotherapy, 71(10), 2909-2917. Oxford University Press
Objectives To describe the population pharmacokinetics of oral amoxicillin and to compare the PTA of current dosing regimens. Methods Two groups, each with 14 healthy male volunteers, received oral amoxicillin/clavulanic acid tablets on two separate
Autor:
Esther Bettiol, Harriet Sommer, Stavros Nikolakopoulos, Isaac Gravestock, Alasdair P. MacGowan, Ohad Amit, Jan Beyersmann, Alexandra McAleenan, Femke de Velde, Johan W. Mouton, Marlieke E. A. de Kraker, Aaron Dane, Andrew M. Lovering, Stéphan Juergen Harbarth, Jean-François Timsit, Martin Wolkewitz, Leonhard Held, Emmanuel Weiss, David Wilson, Teri Ashton
Publikováno v:
Clinical Infectious Diseases, 67(12), 1922-1931. Oxford University Press
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases (2018)
de Kraker, M EA, Sommer, H, de Velde, F, Gravestock, I, Weiss, E, McAleenan, A, Nikolakopoulos, S, Amit, O, Ashton, T, Beyersmann, J, Held, L, Lovering, A M, MacGowan, A, Mouton, J W, Timsit, J-F, Wilson, D, Wolkewitz, M, Bettiol, E, Dane, A & Harbarth, S 2018, ' Optimizing the design and analysis of clinical trials for antibacterials against multidrug-resistant organisms : a white paper from COMBACTE's STAT-Net ', Clinical Infectious Diseases . https://doi.org/10.1093/cid/ciy516
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases (2018)
de Kraker, M EA, Sommer, H, de Velde, F, Gravestock, I, Weiss, E, McAleenan, A, Nikolakopoulos, S, Amit, O, Ashton, T, Beyersmann, J, Held, L, Lovering, A M, MacGowan, A, Mouton, J W, Timsit, J-F, Wilson, D, Wolkewitz, M, Bettiol, E, Dane, A & Harbarth, S 2018, ' Optimizing the design and analysis of clinical trials for antibacterials against multidrug-resistant organisms : a white paper from COMBACTE's STAT-Net ', Clinical Infectious Diseases . https://doi.org/10.1093/cid/ciy516
Innovations are urgently required for clinical development of antibacterials against multidrug-resistant organisms. Therefore, a European, public-private working group (STAT-Net; part of Combatting Bacterial Resistance in Europe [COMBACTE]), has revi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba0798f3d1001f58cb9c96b133ed08d2
https://pure.eur.nl/en/publications/6046230e-b210-4c12-a539-8c06b0b57149
https://pure.eur.nl/en/publications/6046230e-b210-4c12-a539-8c06b0b57149
Publikováno v:
Journal of Antimicrobial Chemotherapy, 69(11), 3163-3164. Oxford University Press
Department of Hospital Pharmacy, Erasmus University Medical Centre, PO Box 2040, 3000 CA Rotterdam, The Netherlands; Department of Paediatric Infectious Diseases and Immunology, Erasmus MC-Sophia Children’s Hospital, University Medical Centre, PO B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1092cbe40f34dcdee791004f47c03d03
https://pure.eur.nl/en/publications/c3142425-c29d-4e31-ba9b-e37c4c7e92b1
https://pure.eur.nl/en/publications/c3142425-c29d-4e31-ba9b-e37c4c7e92b1
Autor:
Jan-Willem C. Alffenaar, Femke de Velde, Ben Greijdanus, A. Mireille A. Wessels, Donald R. A. Uges
Publikováno v:
Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 877(18-19), 1771-1777. ELSEVIER SCIENCE BV
The drug combination rifampicin and clarithromycin is used in regimens for infections Caused by Mycobacteria. Rifampicin is a CYP3A4 inducer while clarithromycin is known to inhibit CYP3A4. During combined therapy rifampicin concentrations may increa